Typical metabolic disorders include, but are not limited to, obesity and diabetes.
AIDP (City of Industry, CA) has gained a U.S. patent for its branded ingredient Magtein magnesium L-threonate in the area of metabolic health. Magtein has been initially promoted as a cognitive-health ingredient.
The patent, No. 8,163,301, is titled “Magnesium compositions and uses thereof for metabolic disorders.” It not only covers Magtein’s unique magnesium compositions but also the use of food, dietary supplements, and drugs containing magnesium L-threonate to combat the effects of metabolic disorder.
Typical metabolic disorders include, but are not limited to, obesity and diabetes. Magtein’s other patents lie in the area of neurological disorders (patent 8,142,803) and food compositions (patent 8,178,132).
New study shows that vitamin K2 as MK-7 may have neuroprotective qualities
May 17th 2024Researchers examined the effects of MK-7 and menaquinone-4 (MK-4) on neuroblastoma cells to understand how different forms of vitamin K2 impact the expression of genes involved in neurodegeneration and neuroinflammation.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.